Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formula:C16H9ClIN3Color and Shape:SolidMolecular weight:405.62BTK inhibitor 13
CAS:<p>BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).</p>Formula:C29H26FN5O3Purity:98%Color and Shape:SolidMolecular weight:511.55BTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Formula:C37H42N8O4Color and Shape:SolidMolecular weight:662.78FGFR-IN-4
CAS:<p>FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.</p>Formula:C24H21N7O2Color and Shape:SolidMolecular weight:439.47HPK1-IN-2 dihydrochloride
CAS:<p>HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].</p>Formula:C19H22Cl2N6OSColor and Shape:SolidMolecular weight:453.39FC 11
CAS:<p>FC 11 is a reversible FAK PROTAC Degrader with DC50 of 40-370 pM and degrades pFAKtyr397 in TM3 cells within 3 hours at 100 nM.</p>Formula:C41H42F3N13O9SColor and Shape:SolidMolecular weight:949.91HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Formula:C27H33N7O3Color and Shape:SolidMolecular weight:503.6Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Formula:C26H31ClN6O2Purity:98%Color and Shape:SolidMolecular weight:495.02HDAC-IN-50
CAS:<p>HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.</p>Formula:C31H41N7O4Color and Shape:SolidMolecular weight:575.7HDAC-IN-63
CAS:<p>HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1.</p>Formula:C25H26Cl2N6O3Color and Shape:SolidMolecular weight:529.42EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Formula:C31H34N6O3Color and Shape:SolidMolecular weight:538.64ALK/EGFR-IN-2
CAS:<p>ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.</p>Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12Irpagratinib
CAS:<p>Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.</p>Formula:C28H32F2N6O5Purity:99.08% - 99.38%Color and Shape:SolidMolecular weight:570.59BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Formula:C20H22Cl2N6OColor and Shape:SolidMolecular weight:433.33EVT801
CAS:<p>EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.</p>Formula:C19H21N5O3Purity:97.4%Color and Shape:SolidMolecular weight:367.4BPR1J-340
CAS:<p>BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.</p>Formula:C29H34N8O3Color and Shape:SolidMolecular weight:542.63CP-547632 TFA
CAS:<p>CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.</p>Formula:C22H25BrF5N5O5SPurity:98%Color and Shape:SolidMolecular weight:646.43JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Formula:C22H23BrFN5O2Purity:98%Color and Shape:SolidMolecular weight:488.35FLT3/ITD-IN-5
CAS:<p>FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.</p>Formula:C23H25N7O2Color and Shape:SolidMolecular weight:431.49AT-9283 L-lactate
CAS:<p>AT-9283 L-lactate is an inhibitor of aurora kinase.</p>Formula:C22H29N7O5Purity:98%Color and Shape:SolidMolecular weight:471.52BCR-ABL-IN-4
CAS:<p>BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).</p>Formula:C27H24ClF2N5O4Color and Shape:SolidMolecular weight:555.96HIF-2α-IN-1
CAS:<p>HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.</p>Formula:C16H8F5NO4SPurity:97.99%Color and Shape:SolidMolecular weight:405.3Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Formula:C30H37N7O2Color and Shape:SolidMolecular weight:527.66BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Formula:C22H25BrN4O2Purity:99.02%Color and Shape:SolidMolecular weight:457.36TIE-2/VEGFR-2 kinase-IN-4
CAS:<p>TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitory</p>Formula:C26H17F4N5O4Color and Shape:SolidMolecular weight:539.44CCT365623 hydrochloride
CAS:<p>CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.</p>Formula:C18H18ClNO4S3Purity:98%Color and Shape:SolidMolecular weight:443.99CT-721
CAS:<p>CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.</p>Formula:C30H29ClN6OPurity:98%Color and Shape:SolidMolecular weight:525.04(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Formula:C16H14N2O2Color and Shape:SolidMolecular weight:266.29FLT3-IN-14
CAS:<p>FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.</p>Formula:C25H24N6O2SColor and Shape:SolidMolecular weight:472.5610Z-Hymenialdisine
CAS:<p>Pan kinase inhibitor</p>Formula:C11H10BrN5O2Purity:98%Color and Shape:Light Yellow SolidMolecular weight:324.13Henatinib
CAS:<p>Henatinib: orally active multi-kinase inhibitor targeting VEGFR-2, c-kit, PDGFR with antitumor effects.</p>Formula:C25H29FN4O4Color and Shape:SolidMolecular weight:468.52Sulfatinib
CAS:<p>Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to</p>Formula:C24H28N6O3SPurity:99.21% - >99.99%Color and Shape:SolidMolecular weight:480.58TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Formula:C26H27Cl2N5O2Purity:98%Color and Shape:SolidMolecular weight:512.43EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Formula:C22H24N6O3Purity:98%Color and Shape:SolidMolecular weight:420.46Larixol
CAS:<p>Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1/2, p38, and AKT phosphorylation critical for</p>Formula:C20H34O2Purity:98%Color and Shape:SolidMolecular weight:306.48Ruxolitinib sulfate
CAS:<p>Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.</p>Formula:C17H20N6O4SColor and Shape:SolidMolecular weight:404.45Risvodetinib
CAS:<p>Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.</p>Formula:C33H34N8O2Color and Shape:SolidMolecular weight:574.68JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Formula:C18H21N4Na2O6PPurity:98%Color and Shape:SolidMolecular weight:466.341ALK/ROS1-IN-1
CAS:<p>ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).</p>Formula:C30H35F3N6O3Purity:98%Color and Shape:SolidMolecular weight:584.63EGFR kinase inhibitor 1
CAS:<p>Potent EGFR blocker; acts on WT, L858R/T790M (IC50: 1.7 nM), less on T790M/C797S; stalls cell cycle, induces apoptosis, deters metastasis.</p>Formula:C30H31N7O2Color and Shape:SolidMolecular weight:521.61BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Formula:C26H22ClN5O3Color and Shape:SolidMolecular weight:487.94FGFR-IN-8
CAS:<p>FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.</p>Formula:C27H31Cl2N9O2Color and Shape:SolidMolecular weight:584.5BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Formula:C26H23N7O2Color and Shape:SolidMolecular weight:465.51CHMFL-FLT3-122
CAS:<p>CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia.</p>Formula:C26H29N7O2Purity:99.63%Color and Shape:SolidMolecular weight:471.55MS 154
CAS:<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Formula:C46H54ClFN8O8Color and Shape:SolidMolecular weight:901.42FGFR-IN-2
CAS:<p>FGFR-IN-2 (compound 1) is a potent inhibitor of FGFR, acting on FGFR1 (IC50: 7.3 nM), FGFR2 (IC50: 4.3 nM), FGFR3 (IC50: 7.6 nM) and FGFR4 (IC50: 11 nM).</p>Formula:C25H30N6O2Color and Shape:SolidMolecular weight:446.54GSK2646264
CAS:<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Formula:C24H26N2O2Color and Shape:SolidMolecular weight:374.48EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Formula:C28H33BrN7O2PColor and Shape:SolidMolecular weight:610.49Infigratinib-Boc
CAS:<p>Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].</p>Formula:C29H35Cl2N7O5Color and Shape:SolidMolecular weight:632.54FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formula:C25H26N6O2Purity:98%Color and Shape:SolidMolecular weight:442.523TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Formula:C17H21FN6OPurity:98%Color and Shape:SolidMolecular weight:344.39Famitinib malate
CAS:<p>Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.</p>Formula:C27H33FN4O7Color and Shape:SolidMolecular weight:544.57Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Formula:C21H33F3N6O11Purity:98%Color and Shape:SolidMolecular weight:602.521PF-06459988
CAS:<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Formula:C19H22ClN7O3Purity:98%Color and Shape:SolidMolecular weight:431.88Roslin 2 bromide
CAS:<p>Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5.</p>Formula:C13H19BrN4Purity:99.34%Color and Shape:SolidMolecular weight:311.22PF-303
CAS:<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Formula:C22H21ClN6O2Color and Shape:SolidMolecular weight:436.89JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Formula:C20H25N5O2Color and Shape:SolidMolecular weight:367.44JNJ-17029259
CAS:<p>JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).</p>Formula:C26H30N6OPurity:98%Color and Shape:SolidMolecular weight:442.56Brolucizumab
CAS:<p>Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.</p>Purity:95%Color and Shape:LiquidEGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Formula:C36H46BrN8O2PColor and Shape:SolidMolecular weight:733.68Atiprimod dimaleate
CAS:<p>Atiprimod Dimaleate is a JAK2 inhibitor.</p>Formula:C30H52N2O8Color and Shape:SolidMolecular weight:568.74BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Formula:C27H28ClFN8O3Purity:99.98%Color and Shape:SolidMolecular weight:567.01ALK/EGFR-IN-1
CAS:<p>ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.</p>Formula:C27H34ClN7O3SPurity:98%Color and Shape:SolidMolecular weight:572.12Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Formula:C25H26ClFN4O4Purity:99.7%Color and Shape:SolidMolecular weight:500.95TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formula:C17H11ClF2N4O2Color and Shape:SolidMolecular weight:376.74SNIPER(TACC3)-11
CAS:<p>SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.</p>Formula:C51H66N10O7S2Color and Shape:SolidMolecular weight:995.26SD 1008
CAS:<p>SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.</p>Formula:C18H19NO5Purity:98%Color and Shape:SolidMolecular weight:329.35Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Formula:C18H21N5O3Purity:99.85%Color and Shape:SolidMolecular weight:355.39DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Formula:C28H27F2N7O3Purity:98%Color and Shape:SolidMolecular weight:547.56Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Formula:C26H29ClN8OColor and Shape:SolidMolecular weight:505.01BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Formula:C21H22Cl2N6OColor and Shape:SolidMolecular weight:445.35UNC4203
CAS:<p>UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.</p>Formula:C30H44N6OColor and Shape:SolidMolecular weight:504.71DW10075
CAS:<p>DW10075, a novel potent and highly selective inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.</p>Formula:C29H23N5O3Color and Shape:SolidMolecular weight:489.52(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Formula:C22H20F2N6O2Purity:98%Color and Shape:SolidMolecular weight:438.43HDAC/JAK/BRD4-IN-1
CAS:<p>HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.</p>Formula:C24H28N6O3Purity:98%Color and Shape:SolidMolecular weight:448.52MTP
CAS:<p>MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.</p>Formula:C29H23F3N4O2Purity:98%Color and Shape:SolidMolecular weight:516.51BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Formula:C16H12BrN5Color and Shape:SolidMolecular weight:354.2EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97ALK/EGFR-IN-3
CAS:<p>ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-</p>Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Formula:C32H28BrF3N6O4SColor and Shape:SolidMolecular weight:729.57SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Formula:C28H35ClFN7O3SColor and Shape:SolidMolecular weight:604.14Pivanex
CAS:<p>Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.</p>Formula:C10H18O4Purity:≥98%Color and Shape:SolidMolecular weight:202.25FLT3/ITD-IN-4
CAS:<p>FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).</p>Formula:C25H22N4O5Color and Shape:SolidMolecular weight:458.47YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Formula:C30H30N4O3Purity:98%Color and Shape:SolidMolecular weight:494.58T338C Src-IN-1
CAS:<p>T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).</p>Formula:C17H20N6O2SPurity:98%Color and Shape:SolidMolecular weight:372.44JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Formula:C20H24N6O2Purity:98%Color and Shape:SolidMolecular weight:380.44MET kinase-IN-3
CAS:<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Formula:C25H16ClF2N5O2Color and Shape:SolidMolecular weight:491.88ALK-IN-6
CAS:<p>ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).</p>Formula:C26H29ClD3N5O3SPurity:98%Color and Shape:SolidMolecular weight:533.1UNC5293
CAS:<p>UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.</p>Formula:C30H42N6O2Color and Shape:SolidMolecular weight:518.69PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Formula:C23H18ClF2N3O2SPurity:98.84%Color and Shape:SolidMolecular weight:473.92TIE-2/VEGFR-2 kinase-IN-3
CAS:<p>TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 values</p>Formula:C23H17F4N5O3SColor and Shape:SolidMolecular weight:519.47Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formula:C20H17N9Purity:98%Color and Shape:SolidMolecular weight:383.41Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Formula:C22H20N6O3Color and Shape:SolidMolecular weight:416.43JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Formula:C19H17N5O4Purity:98%Color and Shape:SolidMolecular weight:379.37KB SRC 4
CAS:<p>KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4</p>Formula:C32H23ClN8Purity:98.83% - 99.34%Color and Shape:SolidMolecular weight:555.03JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Formula:C33H38F2N6O8Color and Shape:SolidMolecular weight:684.69Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Formula:C24H25ClN4O5Purity:99.81%Color and Shape:SolidMolecular weight:484.93BMS-935177
CAS:<p>BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.</p>Formula:C31H26N4O3Purity:99.89%Color and Shape:SolidMolecular weight:502.56Zongertinib
CAS:<p>Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (</p>Formula:C29H29N9O2Purity:98.24%Color and Shape:SolidMolecular weight:535.6
